Comparison of the efficacy of Spironolcatone 5% and Progesterone 2% on hair density and diameter in female pattern hair loss
Phase 4
- Conditions
- Female pattern andrpgenetic alopecia.Androgenic alopecia
- Registration Number
- IRCT201512252581N4
- Lead Sponsor
- Vice Chancellor for research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 36
Inclusion Criteria
female; grade 1 or 2 androgenetic alopecia; no underlying hormonal disorders
Exclusion criteria: patient's decision to exit the study; underlying hormonal disorder; anemia; use of topical medications in the past week; taking oral medications in the past four weeks; have allergy to spironolactone or progesterone; pregnancy or planning to pregnancy or breastfeeding
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hair density per squared cm, Hair diameter. Timepoint: At baseline, 8th, 16th ,24th weeks. Method of measurement: Trichoscopy.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: At baseline, 8th, 16th and 24th weeks. Method of measurement: Qualitative.